Business
Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences
IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the
About this update from Onkure Therapeutics, Inc.
[{"type":"text","content":"IRVINE, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will be participating in five investor conferences during the month of September. Details for the upcoming conferences are as follows: Conference: Citi 16th Annual BioPharma ConferenceDate: September 8-10, 2021Format: One-on-one investor meetings Conference: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: September 13-15, 2021Format: Presentation available for on-demand viewing (beginning 7:00am ET, September 13); one-on-one investor meetings Conference: Baird’s 2021 Global Healthcare ConferenceDate: September 15, 2021Time: 1:20-1:50 PM PTFormat: Presentation and one-on-one investor meetings Conference: SVB Leerink CybeRx Series: Neuromuscular, Rare Diseases & Genetic MedicinesDate: September 22-23, 2021Format: One-on-one investor meetings Conference: Cantor Fitzgerald’s Virtual Global Healthcare ConferenceDate: September 30, 2021Time: 8:40-9:10 AM ETFormat: Presentation and one-on-one investor meetings About Reneo Pharmaceuticals Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes. REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria. Contacts: Joyce AllaireManaging DirectorLifeSci Advisors, [email protected] Vinny JindalChief Financial OfficerReneo Pharmaceuticals, [email protected] \nSource: Reneo Pharmaceuticals, Inc.","length":3893,"tagName":"div"}]